PD-L1 is a key target in immunotherapy strategies, especially those involving immune checkpoint inhibitors. Drugs like pembrolizumab and nivolumab are designed to block the interaction between PD-1 and PD-L1, effectively "releasing the brakes" on the immune system. This allows T-cells to recognize and attack cancer cells more effectively. The efficacy of these drugs can often be correlated with the level of PD-L1 expression on tumor cells.
